Acrivon Therapeutics (ACRV) News Today → get a piece of the profit from this land (From True Market Insiders) (Ad) Free ACRV Stock Alerts $8.89 +0.33 (+3.86%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 2:43 AM | americanbankingnews.comHC Wainwright Equities Analysts Boost Earnings Estimates for Acrivon Therapeutics, Inc. (NASDAQ:ACRV)May 17 at 8:25 AM | marketbeat.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) to Post Q2 2024 Earnings of ($0.48) Per Share, HC Wainwright ForecastsAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) - Investment analysts at HC Wainwright boosted their Q2 2024 earnings estimates for Acrivon Therapeutics in a report issued on Tuesday, May 14th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($0.48) per sMay 17 at 2:42 AM | americanbankingnews.comAcrivon Therapeutics (NASDAQ:ACRV) Rating Reiterated by BMO Capital MarketsMay 15 at 10:04 AM | marketbeat.comAcrivon Therapeutics (NASDAQ:ACRV) Stock Rating Reaffirmed by BMO Capital MarketsBMO Capital Markets reissued an "outperform" rating and issued a $25.00 price objective on shares of Acrivon Therapeutics in a research note on Wednesday.May 15 at 6:55 AM | americanbankingnews.comAcrivon Therapeutics (NASDAQ:ACRV) PT Raised to $22.00May 15 at 3:26 AM | americanbankingnews.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 15 at 3:24 AM | marketbeat.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of "Moderate Buy" from BrokeragesAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight research firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and seven have given a buyMay 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Acrivon Therapeutics, Inc. (ACRV)May 14, 2024 | investorplace.comACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q1 2024May 14, 2024 | globenewswire.comAcrivon Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 11, 2024 | morningstar.comAcrivon Therapeutics Inc ACRVMay 9, 2024 | finance.yahoo.comWhile institutions own 26% of Acrivon Therapeutics, Inc. (NASDAQ:ACRV), private equity firms are its largest shareholders with 50% ownershipApril 30, 2024 | msn.comLadenburg Thalmann Downgrades Acrivon Therapeutics (ACRV)April 29, 2024 | marketbeat.comLADENBURG THALM/SH SH Lowers Acrivon Therapeutics (NASDAQ:ACRV) to NeutralLADENBURG THALM/SH SH downgraded Acrivon Therapeutics from a "buy" rating to a "neutral" rating in a research note on Monday.April 26, 2024 | markets.businessinsider.comBuy Rating on Acrivon Therapeutics with Increased Target Price Amid Promising ACR-368 Trial DataApril 26, 2024 | morningstar.comAcrivon Therapeutics' shares climb 14% on plans to present cancer-test dataApril 26, 2024 | marketbeat.comBMO Capital Markets Raises Acrivon Therapeutics (NASDAQ:ACRV) Price Target to $25.00BMO Capital Markets lifted their price target on Acrivon Therapeutics from $18.00 to $25.00 and gave the stock an "outperform" rating in a research report on Friday.April 25, 2024 | markets.businessinsider.comAcrivon Therapeutics: Strong Buy Recommendation on Impressive AP3 Platform and ACR-368 Data ValidationApril 25, 2024 | markets.businessinsider.comAcrivon Therapeutics: Strong Buy on Impressive Clinical Outcomes and Market PotentialApril 25, 2024 | marketbeat.comAcrivon Therapeutics (NASDAQ:ACRV) Price Target Raised to $17.00 at JMP SecuritiesJMP Securities upped their price objective on Acrivon Therapeutics from $14.00 to $17.00 and gave the company a "market outperform" rating in a research note on Thursday.April 25, 2024 | marketbeat.comTrading was temporarily halted for "ACRV" at 09:04 AM with a stated reason of "LULD pause."April 25, 2024 | marketbeat.comTrading was temporarily halted for "ACRV" at 09:04 AM with a stated reason of "LULD pause."April 25, 2024 | marketbeat.comAcrivon Therapeutics (NASDAQ:ACRV) Earns "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of Acrivon Therapeutics in a report on Thursday.April 24, 2024 | msn.comAcrivon Therapeutics’ shares climb 14% on plans to present cancer-test dataApril 24, 2024 | globenewswire.comAcrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D EventApril 20, 2024 | finance.yahoo.comAcrivon Therapeutics, Inc. (ACRV)April 16, 2024 | finance.yahoo.comAcrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316April 16, 2024 | insidertrades.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Major Shareholder Buys $20,000,500.00 in StockApril 15, 2024 | marketbeat.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Major Shareholder Acquires $20,000,500.00 in StockAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) major shareholder Perceptive Advisors Llc purchased 2,353,000 shares of the company's stock in a transaction dated Thursday, April 11th. The shares were acquired at an average price of $8.50 per share, for a total transaction of $20,000,500.00. Following the purchase, the insider now directly owns 5,360,858 shares of the company's stock, valued at approximately $45,567,293. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.April 12, 2024 | marketbeat.comEquities Analysts Issue Forecasts for Acrivon Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:ACRV)Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) - Equities researchers at HC Wainwright cut their Q1 2024 EPS estimates for shares of Acrivon Therapeutics in a research note issued to investors on Tuesday, April 9th. HC Wainwright analyst E. Bodnar now forecasts that the company will postApril 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Acrivon Therapeutics on Promising Drug Pipeline and Solid FinancialsApril 10, 2024 | globenewswire.comAcrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368April 9, 2024 | markets.businessinsider.comAcrivon To Privately Place $130 Mln Of Shares; Stock Soars In Pre-marketApril 9, 2024 | msn.comAcrivon Therapeutics Stock Is Soaring Tuesday: What's Going On?April 9, 2024 | investorplace.comACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million BoostApril 9, 2024 | globenewswire.comAcrivon Therapeutics Announces $130 Million Private Placement FinancingApril 5, 2024 | marketbeat.comLADENBURG THALM/SH SH Lowers Acrivon Therapeutics (NASDAQ:ACRV) Price Target to $14.00LADENBURG THALM/SH SH lowered their price objective on Acrivon Therapeutics from $18.00 to $14.00 and set a "buy" rating for the company in a research report on Friday.April 1, 2024 | marketbeat.comBMO Capital Markets Reiterates Outperform Rating for Acrivon Therapeutics (NASDAQ:ACRV)BMO Capital Markets reiterated an "outperform" rating and issued a $18.00 price objective on shares of Acrivon Therapeutics in a research note on Monday.April 1, 2024 | markets.businessinsider.comBuy Rating on Acrivon Therapeutics: Anticipated Clinical Validation and Strong Financial PositionMarch 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Acrivon Therapeutics Amid Anticipated Clinical Updates and Platform PotentialMarch 29, 2024 | marketbeat.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Expected to Earn Q1 2024 Earnings of ($0.88) Per ShareAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) - Analysts at HC Wainwright issued their Q1 2024 EPS estimates for shares of Acrivon Therapeutics in a research report issued on Thursday, March 28th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings per share ofMarch 29, 2024 | markets.businessinsider.comBuy Rating Justified by Acrivon Therapeutics’ Clinical Progress and Market PotentialMarch 29, 2024 | markets.businessinsider.comAcrivon Therapeutics: Strong Buy on Promising Clinical Trials and Innovative Drug DevelopmentMarch 28, 2024 | investorplace.comACRV Stock Earnings: Acrivon Therapeutics Misses EPS for Q4 2023March 28, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Acrivon Therapeutics (NASDAQ:ACRV)HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of Acrivon Therapeutics in a research report on Thursday.March 28, 2024 | finanznachrichten.deAcrivon Therapeutics, Inc: Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsMarch 28, 2024 | benzinga.comAcrivon Therapeutics: Q4 Earnings InsightsMarch 28, 2024 | globenewswire.comAcrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsMarch 5, 2024 | globenewswire.comAcrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316March 4, 2024 | finance.yahoo.comAcrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address get a piece of the profit from this land (Ad)This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land. Click here to see my #1 investment for 2024. ACRV Media Mentions By Week ACRV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACRV News Sentiment▼0.710.50▲Average Medical News Sentiment ACRV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACRV Articles This Week▼162▲ACRV Articles Average Week Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Organigram News Today Inventiva News Today Telomir Pharmaceuticals News Today Atossa Therapeutics News Today Lifecore Biomedical News Today Incannex Healthcare News Today Zevra Therapeutics News Today Galectin Therapeutics News Today Greenwich LifeSciences News Today Trevi Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACRV) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingObama’s Forever Term [exposed]Porter & Company4 Cryptos BETTER than BitcoinTrue Market InsidersElon’s New Device is About to Shock the WorldInvestorPlaceUrgent Nvidia WarningAltimetryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
